# Adaptimmune Therapeutics plc (ADAP) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ADAP
## Company Profile
- Ticker: ADAP
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United Kingdom
- Tags: TCR-T Therapy, Oncology
## Stock Data
- Close: Not available
- Market cap: Not available
## Business Overview
Adaptimmune Therapeutics is a cell-therapy company focused on engineered T-cell therapies for cancer. Its platform aims to make T-cell treatment more precise and scalable.
## Why The Stock Is Moving

Current closing-price context is not available for ADAP.

## Geographic Base

Headquartered in the United Kingdom and listed on NASDAQ as an ADR, Adaptimmune has a global cell-therapy profile.

## Business Model

The company depends on clinical validation, manufacturing execution, and the ability to commercialize engineered cell therapy.

## Landscape Position

Adaptimmune is a high-catalyst cell-therapy name whose valuation depends on clinical and launch progress.

## Future Catalysts

- Adaptimmune’s catalysts are Tecelra commercialization and the broader engineered T-cell platform, including lete-cel. The key issue is whether the company can keep turning a cell-therapy platform into an actual commercial franchise.

## Recent News
- 2025-11-17 12:30 EST — [Adaptimmune Announces Changes to Board and Executive Leadership Team](https://biopharmsignal.com/news/ADAP/adaptimmune-announces-changes-to-board-and-executive-leadership-team) — Source: Adaptimmune Therapeutics plc
- 2025-10-20 11:40 EST — [Adaptimmune Announces Delisting from Nasdaq](https://biopharmsignal.com/news/ADAP/adaptimmune-announces-delisting-from-nasdaq) — Source: Adaptimmune Therapeutics plc
- 2025-08-13 11:30 EST — [Adaptimmune Reports Q2 Financial Results and Provides Business Update](https://biopharmsignal.com/news/ADAP/adaptimmune-reports-q2-financial-results-and-provides-business-update) — Source: Adaptimmune Therapeutics plc
- 2025-07-28 11:30 EST — [Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds](https://biopharmsignal.com/news/ADAP/adaptimmune-announces-entry-into-definitive-agreement-for-sale-of-tecelra-lete-cel-afami-cel-and-uza-cel-cell-therapies-to-us-worldmeds) — Source: Adaptimmune Therapeutics plc
- 2025-05-13 11:30 EST — [Adaptimmune Reports Q1 Financial Results and Provides Business Update](https://biopharmsignal.com/news/ADAP/adaptimmune-reports-q1-financial-results-and-provides-business-update) — Source: Adaptimmune Therapeutics plc